Results 71 to 80 of about 12,862 (201)

Sofosbuvir as backbone of interferon free treatments

, 2014
Sofosbuvir is the first-in-class NS5B nucleotide analogues to be launched for hepatitis C virus (HCV) treatment. Its viral potency, pangenotypic activity and high barrier to resistance make it the ideal candidate to become a backbone for several IFN-free
Adhoute, Xavier, Ansaldi, Christelle, Castellani, Paul, Bourlière, Marc, Oules, Valèrie   +4 more
core   +1 more source

Post‐to Pretreatment Ratio of Serum CXCL10 Level Predicts Short‐Term Liver Function Outcome in Compensated and Decompensated Cirrhotic Patients Due to Chronic Hepatitis C Virus Infection After Direct‐Acting Antiviral Therapy

Hepatology Research, Volume 56, Issue 5, Page 840-852, May 2026.
The post‐to pretreatment serum CXCL10 ratio was independently associated with short‐term liver function outcome following HCV eradication in cirrhotic patients. ABSTRACT Aim The prognostic value of serum C‐X‐C motif chemokine ligand 10 (CXCL10) levels for liver function was investigated in hepatitis C virus (HCV)–infected patients with compensated or ...
Takanori Suzuki, Kentaro Matsuura, Yuki Tahata, Hayato Hikita, Masaru Enomoto, Atsunori Tsuchiya, Daiki Miki, Hiroshi Yatsuhashi, Hidekatsu Kuroda, Taro Yamashita, Hitoshi Yoshiji, Nobuharu Tamaki, Seiichi Mawatari, Hisamitsu Miyaaki, Yasuhiro Asahina, Yoichi Hiasa, Yoshihito Uchida, Yasunari Nakamoto, Taro Takami, Takahiro Kodama, Tetsuo Takehara   +20 more
wiley   +1 more source

Combination ledipasvir-sofosbuvir for the treatment of chronic hepatitis C virus infection: a review and clinical perspective

, 2016
Marcel Nkuize,1 Thomas Sersté,1,2 Michel Buset,1 Jean-Pierre Mulkay11Department of Gastroenterology and Hepatology, Saint-Pierre University Hospital, 2Department of Gastroenterology, Pancreatology and Hepatology, Hôpital Academique Erasme ...
Sersté T, Mulkay JP, Nkuize M, Buset M
core  

Treatment of Real-World HCV Genotype 2-Infected Japanese Patients with Sofosbuvir plus Ribavirin

Biology, 2017
The aim of this study was to characterize the treatment response and tolerability of sofosbuvir plus ribavirin therapies in Japanese patients infected with hepatitis C virus (HCV) genotype (GT)-2.
Tatsuo Kanda, Masato Nakamura, Shin Yasui, Yuki Haga, Akinobu Tawada, Eiichiro Suzuki, Yoshihiko Ooka, Koji Takahashi, Reina Sasaki, Shuang Wu, Shingo Nakamoto, Makoto Arai, Fumio Imazeki, Osamu Yokosuka   +13 more
doaj   +1 more source

Targeting Kinetoplastid Parasites with ProTide Prodrugs: A Proof‐of‐Concept Study

ChemMedChem, Volume 21, Issue 7, 14 April 2026.
Neglected tropical diseases (NTDs) remain a major global health challenge, particularly in low‐ and middle‐income countries. Kinetoplastid parasites causing Chagas disease, leishmaniasis, and African trypanosomiasis rely on host purine salvage pathways, making nucleoside analogues attractive therapeutic candidates.
Silvester Lowe, Vishal Satikuvar, Tanjia M. Syeda, Monica Cal, Pascal Mäser, Marcel Kaiser, Hachemi Kadri   +6 more
wiley   +1 more source

Efficacy and safety of sofosbuvir–ledipasvir for treatment of a cohort of Egyptian patients with chronic hepatitis C genotype 4 infection

, 2018
Ossama A Ahmed,1 Hany H Kaisar,1 Rehab Badawi,2 Nehad Hawash,2 Hossam Samir,1 Sherif ST Shabana,1 Mohamed Hassan A Fouad,1 Fatma H Rizk,3 Samy A Khodeir,4 Sherief Abd-Elsalam2 1Department of Internal Medicine, Faculty of Medicine, Ain Shams University ...
Shabana SST, Hawash N, Kaisar HH, Khodeir SA, Abd-Elsalam S, Ahmed OA, Samir H, Badawi R, Fouad MHA, Rizk FH   +9 more
core  

A New Era for Using Natural Pigments: The Case of the C50 Carotenoid Called Bacterioruberin

Biotechnology and Applied Biochemistry, Volume 73, Issue 2, Page 913-926, April 2026.
ABSTRACT Haloarchaea are extremophilic microorganisms belonging to the Archaea domain that require high salt concentrations to live, thus inhabiting ecosystems like salty ponds, salty marshes, or extremely salty lagoons. They are more abundant and widely distributed worldwide than initially expected.
Micaela Giani, Elena Valdés, José María Miralles‐Robledillo, Guillermo Martínez, Carmen Pire, Rosa María Martínez‐Espinosa   +5 more
wiley   +1 more source

Sofosbuvir for the treatment of chronic hepatitis C: between current evidence and future perspectives

, 2014
Elisabetta Degasperi, Alessio AghemoDivision of Gastroenterology and Hepatology, AM and M Migliavacca Center, Fondazione IRCCS Ca' Granda Maggiore Hospital, University of Milan, Milan, ItalyAbstract: In recent years, clinical research in the field of
Degasperi E, Aghemo A
core  

Sofosbuvir-velpatasvir-voxilaprevir in adolescents 12 to 17 years old with HCV infection

, 2022
Sofosbuvir-velpatasvir-voxilaprevir is a pangenotypic regimen for chronic HCV infection. In the USA and Europe, sofosbuvir-velpatasvir-voxilaprevir once daily for 12 weeks is indicated for adults who previously received an HCV NS5A inhibitor.
Leszek Szenborn, Bandita Parhy, Anna Mania, Deirdre Kelly, Chia-Hsiang Hsueh, Sanjay Bansal, Vania Giacomet, Raffaele Iorio, Gabriella Nebbia, Kathryn Kersey, Jiang Shao, Mun Sang Yue, Alessandra Mangia, Guiseppe Indolfi, Malgorzata Pawlowska   +14 more
core   +1 more source

Terapi Kombinasi Sofosbuvir dan Daclatasvir Pada Pasien dengan Hepatitis C Kronik : Sebuah Tinjauan Literatur

, 2023
Latar Belakang: Hepatitis C kronik merupakan penyakit hati yang disebabkan oleh virus hepatitis c/HCV. World Health Organization/WHO melaporkan bahwa lebih dari 3% populasi dunia terinfeksi HCV.
Ary Susilo, Samuel, Hermanto Saputra, Antonius, Derrel Wunnarchie, Malvincent, Odyssey Saint, Hayuningrat, Fitriyah Ashari, Shoimatul   +4 more
core   +1 more source